MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

sciences sciences Making sure you're not a bot! Loading... You are seeing this because the administrator of this website has set up Anubis to protect the server against the scourge of AI companies aggressively scraping websites. This can and does cause downtime for the websites, which makes their resources inaccessible for everyone. Anubis is a compromise. Anubis uses a Proof-of-Work scheme in the vein of Hashcash, a proposed proof-of-work scheme for reducing email spam. The idea is that at individual scales the additional load is ignorable, but at mass scraper levels it adds up and makes scraping much more expensive. Ultimately, this is a placeholder solution so that more time can be spent on fingerprinting and identifying headless browsers (EG: via how they do font rendering) so that the challenge proof of work page doesn't need to be presented to users that are much more likely to be legitimate. Please note that Anubis requires the use of modern JavaScript features that plugins like JShelter will disable. Please disable JShelter or other such plugins for this domain. Protected by Anubis From Techaro . Mascot design by CELPHASE . This website is running Anubis version devel .

Related documents

• Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease risk#234343
• Integrating circulating microRNAs with epidemiological factors enhances breast cancer detection across subtypes: the MCC-Spain study#226465
• LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis#814026
• Biomarker identification of triple negative breast cancer subtypes using machine learning.#342502
• Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer#1047199